<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PSA Rising Prostate Cancer Blog &#187; PCa Treatments</title>
	<atom:link href="http://www.psa-rising.com/blog/category/pca/pca-tx/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.psa-rising.com/blog</link>
	<description></description>
	<lastBuildDate>Thu, 12 Nov 2009 17:35:32 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Obesity as a Factor in Prostate Cancer Treatment Options</title>
		<link>http://www.psa-rising.com/blog/2009/11/obesity-as-a-factor-in-prostate-cancer-treatment-options/</link>
		<comments>http://www.psa-rising.com/blog/2009/11/obesity-as-a-factor-in-prostate-cancer-treatment-options/#comments</comments>
		<pubDate>Fri, 06 Nov 2009 16:39:23 +0000</pubDate>
		<dc:creator>Douglas Scherr M.D.</dc:creator>
				<category><![CDATA[PCa Treatments]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Robotic surgery]]></category>
		<category><![CDATA[BMI]]></category>
		<category><![CDATA[laparoscopic surgery]]></category>
		<category><![CDATA[Obesity]]></category>
		<category><![CDATA[robotic RRP]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=2215</guid>
		<description><![CDATA[BY DOUGLAS SCHERR M.D.
Obesity is becoming an increasing concern with regard to prostate cancer treatment decisions as the number of patients with a Body Mass Index (BMI) of greater than 30 grows.   While there hasn’t been conclusive study into the area, it has been generally found that obesity is a negative risk factor [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/11/obesity-as-a-factor-in-prostate-cancer-treatment-options/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ASTRO Prostate Cancer News Headlines Preview</title>
		<link>http://www.psa-rising.com/blog/2009/10/astro-prostate-cancer-preview/</link>
		<comments>http://www.psa-rising.com/blog/2009/10/astro-prostate-cancer-preview/#comments</comments>
		<pubDate>Sat, 31 Oct 2009 11:05:58 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Beam Radiation]]></category>
		<category><![CDATA[PCa Treatments]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Proton]]></category>
		<category><![CDATA[ASTRO]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=2199</guid>
		<description><![CDATA[The American Society for Radiation Oncology (ASTRO) will host news briefings with accompanying live webcasts on the top cancer research papers from its 51st Annual Meeting to be held this coming week in Chicago. Prostate cancer features in three of briefings. Here are the headlines:
News briefing 1:
Monday, November 2, at 8:00 a.m. (Central); 9:00 a.m. [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/10/astro-prostate-cancer-preview/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Dendreon to seek Provenge approval in November &#8211; Reuters</title>
		<link>http://www.psa-rising.com/blog/2009/09/dendreon-to-seek-provenge-approval-in-november-reuters/</link>
		<comments>http://www.psa-rising.com/blog/2009/09/dendreon-to-seek-provenge-approval-in-november-reuters/#comments</comments>
		<pubDate>Thu, 24 Sep 2009 14:57:22 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[Dendreon]]></category>
		<category><![CDATA[FDA]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=2017</guid>
		<description><![CDATA[Reuters and WAll Street Journal report today that Dendreon plans to seek US FDA approval for Provenge prostate cancer vaccine in November. Dendreon  &#8220;expects regulators to act on the application by the middle of next year, the company said on Thursday.&#8221;
To start from an updated report in the Wall Street Journal, which adds this [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/09/dendreon-to-seek-provenge-approval-in-november-reuters/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Rick Ward: Pioneer Prostate Cancer Activist</title>
		<link>http://www.psa-rising.com/blog/2009/09/rick-ward-pioneer-pca-activist/</link>
		<comments>http://www.psa-rising.com/blog/2009/09/rick-ward-pioneer-pca-activist/#comments</comments>
		<pubDate>Thu, 24 Sep 2009 03:16:14 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Brachytherapy]]></category>
		<category><![CDATA[Early detection]]></category>
		<category><![CDATA[Obits]]></category>
		<category><![CDATA[Obituaries]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[VA]]></category>
		<category><![CDATA[Activism]]></category>
		<category><![CDATA[Prostate Cancer Ribbon]]></category>
		<category><![CDATA[Rick Ward]]></category>
		<category><![CDATA[Seeds]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=2008</guid>
		<description><![CDATA[Rick Ward, of Deer Lodge, Montana and San Antonio,Texas, a pioneering prostate cancer awareness advocate and activist, died recently of chronic obstructive pulmonary disease (COPD). 
Rick, an Air Force veteran aged 71, will be remembered for his tremendous contribution to Seedpods brachytherapy mailing list, for his dedication to helping Veterans faced with cancer and other [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/09/rick-ward-pioneer-pca-activist/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
		</item>
		<item>
		<title>Teleconference: Estrogen Deficiency Side Effects Due to Androgen Deprivation Therapy</title>
		<link>http://www.psa-rising.com/blog/2009/09/teleconference-estrogen-deficiency-side-effects-due-to-androgen-deprivation-therapy/</link>
		<comments>http://www.psa-rising.com/blog/2009/09/teleconference-estrogen-deficiency-side-effects-due-to-androgen-deprivation-therapy/#comments</comments>
		<pubDate>Thu, 10 Sep 2009 21:57:49 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Awareness Events]]></category>
		<category><![CDATA[Hormonal-ADT]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[ADT side-effects]]></category>
		<category><![CDATA[estrogen deficiency]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=1640</guid>
		<description><![CDATA[ Us TOO University Presents:
Estrogen Deficiency Side Effects Due to Androgen Deprivation Therapy.
This free webinar/teleconference with speaker Samir Taneja MD will
take place Wednesday, September 23, 2009, at 8pm Eastern,
7pm Central, 6pm Mountain, 5pm Pacific.
For more information and to RSVP today, go to:
http://www.ustooevents.org/site/Survey?ACTION_REQUIRED=URI_ACTION_USER_REQUESTS&#038;SURVEY_ID=2700
]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/09/teleconference-estrogen-deficiency-side-effects-due-to-androgen-deprivation-therapy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Fatigue From Radiotherapy May Be Caused by Inflammation</title>
		<link>http://www.psa-rising.com/blog/2009/08/fatigue-radiation-inflammation/</link>
		<comments>http://www.psa-rising.com/blog/2009/08/fatigue-radiation-inflammation/#comments</comments>
		<pubDate>Mon, 24 Aug 2009 04:09:33 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Beam Radiation]]></category>
		<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Prostate Cancer]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=1475</guid>
		<description><![CDATA[Patients who experience fatigue during radiotherapy for breast or prostate cancer may be reacting to activation of the proinflammatory cytokine network, a known inflammatory pathway, according to a report in Clinical Cancer Research, a journal of the American Association for Cancer Research.

• Fatigue is a major side effect of radiotherapy
• Inflammation mechanism suggests possible treatment [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/08/fatigue-radiation-inflammation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer</title>
		<link>http://www.psa-rising.com/blog/2009/08/denosumab-in-men-receiving-androgen-deprivation-therapy-for-prostate-cancer/</link>
		<comments>http://www.psa-rising.com/blog/2009/08/denosumab-in-men-receiving-androgen-deprivation-therapy-for-prostate-cancer/#comments</comments>
		<pubDate>Thu, 20 Aug 2009 12:48:46 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Denosumab]]></category>
		<category><![CDATA[Hormonal-ADT]]></category>
		<category><![CDATA[Osteoporosis]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Side Effects]]></category>
		<category><![CDATA[trial results]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=1425</guid>
		<description><![CDATA[Androgen-deprivation therapy is well-established for treating prostate cancer but is associated with bone loss and an increased risk of fracture. Matthew R. Smith and an international team investigated the effects of denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor-{kappa}B ligand, on bone mineral density and fractures in men receiving androgen-deprivation therapy [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/08/denosumab-in-men-receiving-androgen-deprivation-therapy-for-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sen. Chris Dodd&#8217;s Prostate Cancer Covered by Congressional Health Plan</title>
		<link>http://www.psa-rising.com/blog/2009/07/sen-chris-dodds-prostate-cancer-covered-by-congressional-health-plan/</link>
		<comments>http://www.psa-rising.com/blog/2009/07/sen-chris-dodds-prostate-cancer-covered-by-congressional-health-plan/#comments</comments>
		<pubDate>Sat, 01 Aug 2009 02:05:35 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Healthcare Reform]]></category>
		<category><![CDATA[PSA Test]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Surgery]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=1372</guid>
		<description><![CDATA[Senator Christopher J. Dodd of Connecticut, age 65, announced on Friday that he had prostate cancer, in an early, treatable form. His PSA blood test, taken during an annual physical exam, plus follow up biopsy and treatment are covered by his Congressional health care plan, he said.

Dodd said that a blood test during an annual [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/07/sen-chris-dodds-prostate-cancer-covered-by-congressional-health-plan/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sandoz launches generic version of Casodex® tablets</title>
		<link>http://www.psa-rising.com/blog/2009/07/sandoz-launches-generic-casodex/</link>
		<comments>http://www.psa-rising.com/blog/2009/07/sandoz-launches-generic-casodex/#comments</comments>
		<pubDate>Thu, 09 Jul 2009 07:50:41 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Casodex]]></category>
		<category><![CDATA[Hormonal-ADT]]></category>
		<category><![CDATA[PCa Treatments]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=1647</guid>
		<description><![CDATA[Princeton, New Jersey; July 9, 2009 &#8212; Sandoz today announced the introduction of bicalutamide tablets, USP a generic equivalent of Casodex®, in the United States. Bicalutamide is an androgen receptor inhibitor indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of the prostate. [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/07/sandoz-launches-generic-casodex/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Proton Therapy On Pres. Obama&#8217;s Health-Care Hatchet List?</title>
		<link>http://www.psa-rising.com/blog/2009/07/is-proton-beam-therapy-on-obamas/</link>
		<comments>http://www.psa-rising.com/blog/2009/07/is-proton-beam-therapy-on-obamas/#comments</comments>
		<pubDate>Wed, 08 Jul 2009 14:34:47 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Beam Radiation]]></category>
		<category><![CDATA[PCa Treatments]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Proton]]></category>
		<category><![CDATA[Side Effects]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=1318</guid>
		<description><![CDATA[Proton beam therapy for prostate cancer, a treatment that attracts more than an average numbers of engineers, scientists and pilots, is coming under intense scrutiny from reporters who expect it to be questioned by the Obama adminstration&#8217;s health-care reform team.
In an article in today&#8217;s New York Times, &#8220;In Health Reform, a Cancer Offers an Acid [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/07/is-proton-beam-therapy-on-obamas/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
